Abstract Search

ea0063p1107 | Pituitary and Neuroendocrinology 3 | ECE2019

European observational study of ketoconazole for endogenous cushing’s syndrome in collaboration with European registry on cushing’s syndrome ERCUSYN: PASS ketoconazole study design and rationale

Bostnavaron Martine , Marsault Pauline , Arosio Maura , Bertherat Jerome , Brue Thierry , Chabre Olivier , Chanson Philippe , Duarte Joao Sequeira , Fajardo Carmen , Feelders Richard , Alexandra Hanzu Felicia , Kastelan Darko , Netea-Maier Romana , Newell-Price John , Pereira Alberto , Ragnarsson Oskar , Reincke Martin , Strasburger Christian , Tabarin Antoine , Touraine Philippe , Trainer Peter , Pal Aparna , Zopf Kathrin , Franz Holger , Stalla Gunter , Santos Alicia , Valassi Elena , Werner Sandy , Webb Susan

Introduction and rationale: Cushings syndrome (CS) is a rare disease with hypercortisolism caused either by ACTH excess from a pituitary or non-pituitary tumor or by an ACTH-independent primary adrenal overproduction of cortisol. It is associated with significant comorbidities potentially lethal: hypertension, diabetes, coagulopathy, cardiovascular disease, infections, and osteoporotic fractures. It is usually managed by surgery and/or medical treatment with steroidogene...

0 shares

ea0070aep661 | Pituitary and Neuroendocrinology | ECE2020

Metyrapone treatment in endogenous Cushing’s syndrome. Results from a prospective multicenter, open-label, phase III/IV study: Prompt

Nieman Lynnette , Boscaro Marco , Carla Scaroni , Deutschbein Timo , Mezosi Emese , Driessens Natacha , Emanuela Georgescu Carmen , Hubalewska-Dydejczyk Alicja , Berker Dilek , Jarzab Barbara , Maiter Dominique , Reincke Martin , Loli Paola , Zampetti Benedetta , Atmaca Aysegul , Badiu Corin , Beckers Albert , Bolanowski Marek , Cavagnini Francesco , Unger Nicole , Giordano Roberta , Hanzu Felicia , Terzolo Massimo , Bostnavaron Martine , Marsault Pauline , Toth Miklos

Metyrapone treatment in endogenous Cushing’s syndrome. Results from a prospective multicenter, open-label, phase III/IV study: PROMPTBackground: Metyrapone is a steroidogenesis inhibitor approved in Europe for the treatment of endogenous Cushing’s syndrome (CS) based on observational retrospective studies published over more than 50 years. We present data from the first prospective study designed to confirm metyrapone efficacy and good tolera...

0 shares

Endocrine Abstracts

European observational study of ketoconazole for endogenous cushing’s syndrome in collaboration with European registry on cushing’s syndrome ERCUSYN: PASS ketoconazole study design and rationale

Metyrapone treatment in endogenous Cushing’s syndrome. Results from a prospective multicenter, open-label, phase III/IV study: Prompt

BiosciAbstracts